Utidelone has been selected twice for oral presentations at the ASCO annual meeting and approved in 2021 for the treatment of mBC.
-
Honors Course -
PipelineBuilding balanced and differentiated pipeline covering products from early- to late-stage through both in-house development and in-licensing.
-
PartnershipWe are actively selecting partners through in/out- licensing and co-development to build differentiated pipeline and to achieve win-win situation.
-
Enterprise micro filmWhat does innovative anti-cancer drug development mean to patients, investigators and Biostar, respectively?
News
-
2023-06-16Company News
FDA Approved Utidelone Injectable (UTD1) Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer -
2023-06-12Company NewsBiostar Pharma Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule (UTD2)—The World's First Oral Epothilone Anti-Cancer Drug
